Antibody biotech Abpro taps SPAC to get back on Nasdaq track 5 years after axed IPO

22 Sep 2023
www.fiercebiotech.com
IPOAcquisition
Antibody biotech Abpro taps SPAC to get back on Nasdaq track 5 years after axed IPO
Preview
Source: FierceBiotech
Celltrion invested in Abpro and offered up to $1.75 billion in milestones for an asset.
Abpro is taking a second run at the public markets. Five years after pulling out of a planned IPO, the antibody specialist is back with a special purpose acquisition company, agreeing to combine with Atlantic Coastal Acquisition Corp. II to secure a Nasdaq listing and cash for a pipeline dominated by preclinical immuno-oncology programs.
The press release gives Abpro an implied equity valuation of $725 million but makes no mention of how much the transaction will add to the biotech’s bank balance. Atlantic Coastal put $306 million in a trust account after it closed its IPO early last year but redemptions later decimated its holdings. In April, stockholders redeemed shares worth $276 million, leaving $36 million in the account at the end of June.
Abpro will use whatever proceeds it receives to fund a pipeline that is, with the notable exception of the addition of a midphase COVID-19 program, very similar to the set of candidates that were in development at the time of the failed IPO attempt in 2018.
Back then, Abpro listed a HER2xCD3 T-cell engager, ABP-100, as its lead program. The candidate was in IND-enabling studies then and seems to still be there now, according to Abpro’s website, but is nearing phase 1. Abpro had two other candidates at the IND-enabling stage at the time of its IPO filing. One asset, a ligand trap for eye diseases, is still at the same stage; the other is no longer part of the pipeline.
Additions to the immuno-oncology pipeline include a candidate that targets CD3 and Claudin18.2, one of the hottest targets in cancer, and another HER2xCD3 bispecific that landed Abpro a deal with Celltrion. The Korean biotech invested in Abpro and offered up to $1.75 billion in milestones for the global rights.
The most advanced addition to the pipeline is a SARS-CoV-2 antibody, an approach that made waves early in the pandemic but was later nullified by the rise of new variants. Abpro began a phase 2/3 clinical trial of its lead COVID-19 candidate, ABP-300, late in 2020. One year later, the biotech touted the effect of its follow-up candidate, ABP-310, against omicron and targeted emergency use authorization in 2022.
Updates on the COVID-19 program dried up after the omicron statement. Abpro has filed to raise money twice in recent years, offering $40 million in 2020 and $80 million in 2022. At the time of the filings, the biotech had sold $18 million in the first offering and $2 million in the second offering.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.